MONOPAR, SINGAPORE UNIVERSITY CANCER PRECLINICAL EVALUATION COLLABORATION

KUALA LUMPUR, June 4 (Bernama) -- Monopar Therapeutics Inc has entered into a collaboration agreement with the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS) to evaluate the activity of MNPR-202 and related analogues in multiple types of cancer.

In a statement, the clinical-stage biopharmaceutical company said MNPR-202 was designed to retain the same potentially non-cardiotoxic backbone as camsirubicin but is modified at other positions.

It may enable it to work in certain cancers that are resistant to camsirubicin and doxorubicin.

Monopar recently announced a composition of matter US patent (US10,450,340) covering MNPR-202 and related analogues.

While camsirubicin is expected to enter a dose escalation run-in clinical trial in advanced soft tissue sarcoma in the second half of this year, CSI Singapore will explore how the immune system recognises cancer cells treated with MNPR-202 and related analogues.

This is to guide the rational design of immunotherapy-chemotherapy combinations for cancer treatment.

CSI Singapore is one of Asia’s premier cancer research centres and NUS is consistently ranked as one of the world's top universities.

“We believe MNPR-202 has the potential to disrupt the current chemotherapy landscape and impact a broad range of cancers,” said Dr Anand Jeyasekharan, who will be the Principal Investigator at CSI Singapore.

MD, CEO of Monopar, Chandler Robinson said a world-class reputation paired with deep expertise on the relationship between chemotherapy and immune cell activation made Dr Jeyasekharan and CSI Singapore a great research partner.

-- BERNAMA